For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2018
At a glance
- Drugs PSMA 617 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Jun 2018 Interim results (n=50) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 According to Endocyte media release, data from this trial was presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 09 May 2018 Results presented in an Endocyte media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History